ARLINGTON, Va., July 28 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) today said it will hold a telephonic media briefing on Monday, July 31, beginning at 10:00 AM, to unveil an analysis that conclusively demonstrates that the anti-competitive brand pharmaceutical practice of introducing authorized generics (AGs) "significantly reduces incentives for independent generic firms to challenge invalid brand name patents and to develop non-infringing processes and provide no consumer savings."
Representatives of the GPhA and the study's authors will present the findings on the conference call and respond to media questions. The number to call to participate in the briefing is: 800-311-9407 and the passcode is GPHA.REPORT.
GPhA's independent analysis raises serious questions about the validity of the recent PhRMA study on authorized generics, noting that factors such as an inconsistent choice of data, inadequate data points and the use of wholesale instead of retail prices resulted in "significant problems" and that the errors create great concerns regarding the utility of the conclusions provided by it.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 56% of the total prescriptions dispensed in the United States, but less than 13.1% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.
Generic Pharmaceutical Association
CONTACT: Andrea Hofelich, +1-703-647-2495, for GPhA